Menopause Experience Differs by Ethnic Group

BY DAMIAN MCNAMARA
Miami Bureau

LAKE BUENA VISTA, Fla. — Menopause symptoms vary significantly by ethnic group, based on data emerging from a longitudinal study.

The acculturation of women immigrants to the United States, as well as their socioeconomic status, are two factors that might account for these differences, said Dr. Nanette F. Santoro, an endocrinologist who has coauthored multiple studies based on data from the Study of Women’s Health Across the Nation (SWAN).

The study included women from seven sites: Boston; Newark, N.J.; Pittsburgh; Chicago; Oakland, Calif.; and Los Angeles. Each site recruited white women and women from one ethnic minority group: black, Hispanic, Chinese, or Japanese. More than 10 years later, about 85% of the participants remain in the study.

“We found differences by ethnicity—very intriguing differences,” Dr. Santoro said.

For example, in one study of 11,652 women from SWAN, Dr. Santoro and her colleagues found that 126 participants (1.1%) reported onset of menopause before age 40 years, a condition known as premature ovarian failure (Hum Reprod. 2003;18:199-206). This occurred in 1.4% of both black and Hispanic women, 1.0% of white women, 0.5% of Chinese women, and 0.1% of Japanese women. (See bar chart.) These differences were deemed statistically significant.

In contrast to other minorities, Hispanic women in SWAN and similar studies tend to improve little or even worsen in terms of health after they have been assimilated into U.S. culture.

Acculturation of immigrants is “a double-edged sword,” Dr. Santoro said at the annual meeting of the North American Menopause Society. It can improve socioeconomic status, access to health care, and attainment of higher education, but at the same time can worsen health through acculturative stress.

In contrast to other minorities, Hispanic women in SWAN and similar studies tend to improve little or even to worsen in terms of health once they are assimilated, she said. Watch for the “Hispanic paradox.” Health outcomes are worse among this population with increased acculturation, despite better socioeconomic status, because of factors such as higher rates of teen pregnancy and cigarette smoking, said Dr. Santoro, director of the division of reproductive endocrinology and infertility at Albert Einstein College of Medicine, New York.

She cautioned, however, that the Hispanic population is heterogeneous and cannot be addressed as a single entity. The Hispanic SWAN participants came from many different countries and cultures and displayed some internal differences. For example, women from Puerto Rico were more vulnerable to acculturation and reported more menopause-related sleep problems and depressive symptoms than did other Hispanics.

Meanwhile, the acculturation of Japanese women was associated with fewer menopausal symptoms than were seen in Hispanics. Similarly, Chinese participants reported fewer symptoms compared with white, black, and Hispanic women in SWAN. “There are clear-cut differences in symptom reporting by ethnic group,” Dr. Santoro said.

Hispanic and black women were more likely to report depressive symptoms, and Chinese and Japanese women were less likely to do so, the study found.

“This is confounded, possibly, by lower socioeconomic status in the African American and Hispanic groups, and a higher socioeconomic status in Chinese and especially Japanese women,” she said.

Black women in SWAN reported the most hot flashes. Dr. Santoro proposed that increased adiposity among these women might provide more insulation and make them less heat tolerant.

Black women, however, were less bothered by hot flashes than were Hispanic women, who reported more embarrassment with vasomotor symptoms.

SWAN is supported by grants from the Department of Health and Human Services.

Long-Term OCs Can Prevent Endometrioma Recurrence

BY DOUG BRUNK
San Diego Bureau

LAS VEGAS — After laparoscopic cystectomy, the long-term use of oral contraceptives can effectively prevent recurrence of ovarian endometrioma, based on results from a single-center study.

In the 2-year study of 217 patients, two groups got either cyclic or continuous oral contraceptives after laparoscopic cystectomy, and one group went untreated.

The recurrence rate for endometriomas was 29% in the untreated group, a rate that was significantly higher than the recurrence rates in the groups who took OCs.

“Oral contraceptive pills can provide a better option in terms of safety, tolerability, and cost,” than do other hormones for adjuvant therapy following laparoscopic surgery, Dr. Mohamed Mabrouk said at the annual meeting of the AAGL. “However, data from clinical trials on this topic are few and controversial.”

In one cohort study, long-term exposure to oral contraceptives after conservative surgery for ovarian endometriosis was associated with a major reduction in the risk of endometrioma recurrence, with a gradient effect observed with regard to duration of treatment (Am. J. Obstet. Gynecol. 2008;198:564.e1-5).

Although researchers in an earlier retrospective study found that treatment with oral contraceptives for a mean of 9.5 months after laparoscopic excision did not significantly influence endometrioma recurrence, they did suggest that a longer period of treatment might prevent recurrence (Hum. Reprod. 2006;21:2171-4).


However, in this trial, OCs were administered for only 6 months after the operation, said Dr. Mabrouk of the minimally invasive gynecologic surgery unit at the University of Bologna (Italy).

“Based on our observational process, we noticed that patients who used oral contraceptives for a longer period of time had lower recurrence rates,” he explained. “So we hypothesized that the length of treatment seems to be an important factor in the long-term efficacy of therapy.”

To test this hypothesis, he and his associates conducted a randomized trial to evaluate the efficacy of long-term cyclic and continuous administration of monophasic, combined low-dose oral contraceptives in preventing endometrioma recurrence in 217 patients (mean age, 29 years) who underwent laparoscopic cystectomy at the university.

Every 6 months for 24 months, the researchers conducted clinical and ultrasonographic studies of all patients, noting the presence of recurrence (defined as the presence of an ovarian endometrioma measuring more than 1.5 cm in diameter), time of recurrence, size of recurrent endometrioma, and increase in mean diameter.

Of the 217 patients, 69 received no therapy, 75 got cyclic oral contraceptives, and 73 received continuous oral contraceptives. The contraceptives contained 0.020 mg ethinylestradiol and 0.075 mg gestodene. At 2 years’ follow-up, 37 endometrioma recurrences were detected in the three groups. Nearly two-thirds of the recurrences (65%) took place between 12 and 18 months after surgery.

The recurrence rate was 29% in the untreated group, a rate that was significantly higher than the recurrence rates in the groups who took OCs (15% for the cyclic therapy group, and 8% for the continuous therapy group).

The mean diameter of recurrent endometrioma in the untreated patients at 2 years’ follow-up was 2.73 cm, which was significantly larger than the mean diameter in the treated groups (2.17 cm in the cyclic therapy group and 1.71 cm in the continuous therapy group).

“Our study showed that the mean diameter of recurrent cysts at first observation was significantly smaller in cyclic and continuous users, proving that oral contraceptives can even influence disease expression and reduce its severity,” Dr. Mabrouk said.

He also reported that the mean increase in diameter in the untreated group at every 6 months of follow-up was 0.48 cm, which was significantly larger than that for the treated patients (0.31 cm for the cyclic group vs. 0.25 cm for the continuous group).

No statistically significant differences were observed between the treated groups in terms of the number, size, and growth of recurrent endometriomas.

“However, there was a positive trend in patients receiving continuous therapy regarding size and growth of recurrent endometriomas,” he reported.

Dr. Mabrouk stated that he had no relevant financial disclosures to report.